Parallel Advisors’s Stoke Therapeutics STOK Stock Holding History

Parallel Advisors’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13	Closed	-$423	–	4064
2026 Q1	$423	Hold	13	–	–	﹤0.01%	3697
2025 Q4	$413	Buy	+13	New	+$391	﹤0.01%	3431
2025 Q2	–	Sell	-24	Closed	-$160	–	3692
2025 Q1	$160	Buy	+24	New	+$224	﹤0.01%	3411
2023 Q3	–	Sell	-57	Closed	-$606	–	3482
2023 Q2	$606	Hold	57	–	–	﹤0.01%	3061
2023 Q1	$475	Hold	57	–	–	﹤0.01%	3134
2022 Q4	$526	Buy	+57	New	+$593	﹤0.01%	3025

Other funds holding STOK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Parallel Advisors's STOK Position: Q2 2026 in Review

Parallel Advisors sold out of Stoke Therapeutics (STOK) in Q2 2026, closing a stake of 13 shares — an estimated $423 sold.

Parallel Advisors first reported a position in STOK in Q4 2022 and held it in 6 quarters. The position peaked at $606 in Q2 2023. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

Parallel Advisors reported no remaining Stoke Therapeutics position as of Q2 2026 after selling out during the quarter.
Parallel Advisors sold 13 Stoke Therapeutics shares in Q2 2026, an estimated $423.
Parallel Advisors first reported a position in Stoke Therapeutics in Q4 2022 and held it in 6 quarters.
Parallel Advisors's Stoke Therapeutics position peaked at $606 in Q2 2023.
197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.